论文部分内容阅读
目的评价蒙脱石散治疗消化性溃疡的临床疗效及安全性。方法将100例患者随机分为蒙脱石散组和胶粒次枸橼酸铋组,各50例。蒙脱石散组采用蒙脱石散剂每次3 g,tid,疗程4~6周;胶粒次枸橼酸铋组每次0.12 g,每日4次,于餐前及睡前30 min服用。结果蒙脱石散组患者经治疗后有效率为92.0%,胶粒次枸橼酸铋组有效率为68.0%,两组疗效比较差异有统计学意义(P<0.05)。除腹胀外,两组其他症状缓解情况差异均有统计学意义(P<0.05)。便秘蒙脱石散组3例,胶体次枸橼酸铋组1例,两者不良反应发生率差异无统计学意义(P>0.05)。结论蒙脱石散治疗消化性溃疡的疗效较好,不良反应少,对肝、肾功能无影响,是一种安全有效的药物,值得推广。
Objective To evaluate the clinical efficacy and safety of montmorillonite in the treatment of peptic ulcer. Methods 100 patients were randomly divided into montmorillonite powder group and colloidal bismuth citrate group, each 50 cases. Montmorillonite powder group with montmorillonite powder each 3 g, tid, treatment for 4 to 6 weeks; colloidal bismuth subgroup each time 0.12 g, 4 times a day, before and at bedtime to take 30 min . Results After treatment, the effective rate was 92.0% in the montmorillonite group and 68.0% in the colloidal bismuth citrate group, the difference between the two groups was statistically significant (P <0.05). In addition to abdominal distension, the differences of other symptoms between the two groups were statistically significant (P <0.05). Constipation montmorillonite powder group 3 cases, colloidal bismuth subgroup 1 case, the difference between the two adverse reactions was not statistically significant (P> 0.05). Conclusions Montmorillonite powder is a safe and effective treatment of peptic ulcer with good curative effect, few side effects and no effect on liver and kidney function. It is worth popularizing.